ReviewClinicopathological and prognostic significance of FoxM1 in gastric cancer: A meta-analysis

- The effects of FoxM1 in gastric cancer still exist different arguments.
- FoxM1 was associated with TNM stage, depth of invasion, lymph node metastasis and poor prognosis in the patients with gastric cancer.
- FoxM1 is a candidate novel prognostic biomarker for the patients with gastric cancer.

BackgroundThe relationship between expression of FoxM1 and clinical parameters of patients with gastric cancer (GC) has yet to be fully established.MethodsA systematic search was performed. Odds ratio (OR) and confidence interval (CI) were used to assess association between expression of FoxM1 and clinical parameters and the prognostic value of patients with GC.ResultsEight studies involving 529 patients with GC were identified. Overall, the pooled results showed that expression of FoxM1 was associated with TNM stage (OR: 0.482, 95%CI: 0.275-0.845, P = 0.011), depth of invasion (OR: 0.617, 95%CI: 0.382-0.998, P = 0.049) and lymph node metastasis (OR: 2.084, 95%CI: 1.305-3.328, P = 0.002) in the patients with GC. Whereas, expression of FoxM1 was not associated with gender (OR: 1.143, 95%CI: 0.726-1.799, P = 0.564) and tumors' differentiation (OR: 0.991, 95%CI: 0.624-1.575, P = 0.971) of GC. Expression of FoxM1 was also associated with poor prognosis of overall survival (OS) in the patients with GC (one year OS: OR: 0.218, 95%CI: 0.103-0.459, P = 0.000; three years OS: OR: 0.178, 95%CI: 0.093-0.340, P = 0.000; five years OS: OR: 0.180, 95%CI: 0.095-0.341, P = 0.000).ConclusionExpression of FoxM1 is associated with TNM stage, depth of invasion, lymph node metastasis and poor prognosis of the patients with GC.